Enalaprilat dihydrate

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：Enalaprilat dihydrate	Purity：99% min
CAS NO：84680-54-6	Solubility：DMSO : ≥ 100 mg/mL (260.13 mM)
Molecular Formula：C₁₈H₂₈N₂O₇	Package：Package according to customer requirements
Molecular Weight：384.424	Storage：Store at -20℃

Quality control

Remarks

Enalaprilat has high affinity for human endothelial ACE with IC₅₀ of 1.94 nM in vitro binding assay by displacing a saturating concentration of [¹²⁵I]351A, a radiolabeled lisinopril analogue from ACE binding sites, and shows bradykinin/angiotensin I selectivity ratio of 1.00 calculated from double displacement experiments. Enalaprilat attenuates the IGF-I induced neonatal rat cardiac fibroblast growth (30% reduction) in a concentration-dependent fashion, with IC₅₀ of 90 mM.

Properties:

Boiling Point: 563.5ºC at 760 mmHg

Melting Point: 151-159ºC

Flash Point: 294.6ºC

Refractive Index: 1.579

RAAS Inhibitors Related Prodcuts:

Aliskiren hemifumarate; Candesartan; Candesartan Cilexetil; Losartan potassium; Irbesartan; PD123319; Perindopril Erbumine; Ramipril; Captopril; Azilsartan; VTP-27999 TFA; Eprosartan Mesylate; Telmisartan; Valsartan; Enalapril Maleate ; Benazepril

References

[1]. Ceconi, C., et al., Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol, 2007. 577(1-3): p. 1-6.

[2]. van Eickels, M., H. Vetter, and C. Grohe, Angiotensin-converting enzyme (ACE) inhibition attenuates insulin-like growth factor-I (IGF-I) induced cardiac fibroblast proliferation. Br J Pharmacol, 2000. 131(8): p. 1592-6.